AUROPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | AUROPHARMA | Market Cap | 83,125 Cr. | Current Price | 1,431 ₹ | High / Low | 1,460 ₹ |
| Stock P/E | 38.8 | Book Value | 369 ₹ | Dividend Yield | 0.28 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,321 ₹ | DMA 200 | 1,223 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 64.1 | MACD | 30.4 | Volume | 18,79,791 | Avg Vol 1Wk | 12,68,169 |
| Low price | 1,016 ₹ | High price | 1,460 ₹ | PEG Ratio | 9.08 | Debt to equity | 0.21 |
| 52w Index | 93.5 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 30.9 |
📊 AUROPHARMA shows moderate fundamentals with ROE (8.65%) and ROCE (10.8%), supported by manageable debt (0.21). The company trades at a P/E of 38.8, higher than the industry average of 30.9, suggesting mild overvaluation. The PEG ratio of 9.08 indicates expensive growth relative to earnings. Dividend yield is modest at 0.28%. Quarterly profit growth (+26%) is encouraging, but valuations remain stretched.
💡 Ideal Entry Zone: ₹1,200 – ₹1,300, closer to its 200 DMA (₹1,223), as current price (₹1,431) is near its 52-week high. RSI at 64.1 indicates mildly overbought conditions, while MACD is positive, suggesting short-term bullishness.
📈 Exit / Holding Strategy: If already holding, consider a long-term horizon (3–5 years) given stable fundamentals and industry tailwinds. Partial profit booking near ₹1,450–₹1,460 could be prudent, while retaining a core position for long-term compounding. Monitor earnings growth and institutional flows closely.
✅ Positive
- Quarterly profit growth (+26%).
- EPS at ₹36.7 provides a solid earnings base.
- FII holdings increased (+1.29%), showing foreign investor confidence.
⚠️ Limitation
- ROE (8.65%) and ROCE (10.8%) are modest compared to peers.
- PEG ratio (9.08) indicates expensive growth.
- Dividend yield (0.28%) is low for income investors.
📉 Company Negative News
- DII holdings decreased (-1.84%), showing reduced domestic institutional confidence.
- Valuations remain stretched compared to industry average.
📈 Company Positive News
- Quarterly profit growth (+26%) supports earnings momentum.
- Strong FII inflows indicate global investor trust.
🏭 Industry
- Industry P/E is 30.9, lower than AUROPHARMA’s 38.8.
- Pharmaceutical sector remains defensive with steady demand.
🔎 Conclusion
AUROPHARMA is a fundamentally stable company with moderate returns and strong recent earnings growth. However, valuations are stretched, making it suitable for long-term investors only at lower entry levels (₹1,200–₹1,300). Existing holders can remain invested for 3–5 years, with partial profit booking near highs. Monitoring institutional flows and quarterly earnings is essential for sustained conviction.